News

Ad hoc announcement pursuant to Art. 53 LR

Resilient Performance with Strong Profit Gains in Challenging Markets

medmix’ Drug Delivery (“Haselmeier”) showcased the proven innovation behind its PiccoJect™ platform for high-viscosity drugs at the international conferences PDA Universe in Vienna and PODD in Boston.

medmix wins one of the largest new Beauty businesses in company history and strengthens position in key global beauty markets with facility extensions

medmix has partnered with Gurit, a global leader in advanced composite materials, to advance sustainable solutions for industrial bonding applications.

Ad hoc announcement pursuant to Art. 53 LR

Increased profitability despite subdued revenues

medmix has been recognized as one of only nine Swiss companies to achieve an "A" score in CDP's annual climate change assessment, placing it in a select group of global environmental leaders

At today’s annual general meeting (AGM) of medmix Ltd., shareholders approved all proposals of the Board of Directors. medmix will pay an ordinary dividend of CHF 0.50 per share.

Ad hoc announcement pursuant to Art. 53 LR

Robust performance in challenging market environment

medmix Switzerland AG has been named a winner in the 2024 BIG Sustainability Awards presented by the Business Intelligence Group. This achievement complements the company's BIG Innovation Award in January 2024 for its MIXPAC™ greenLine™ 400 mL 1:1 two-component cartridge set.

Ad hoc announcement pursuant to Art. 53 LR

First half broadly in line with expectations, with Dental recovery on track
Full-year 2024 guidance reduced to reflect ongoing softness in end markets

medmix asserts trademark rights to protect quality and consumer safety

At today’s annual general meeting (AGM) of medmix Ltd, shareholders approved all proposals of the Board of Directors. medmix will pay an ordinary dividend of CHF 0.50 per share to shareholders.